<DOC>
	<DOCNO>NCT00516607</DOCNO>
	<brief_summary>RATIONALE : Enzastaurin may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving enzastaurin together temozolomide may kill tumor cell . PURPOSE : This phase I trial study side effect best dose enzastaurin give together temozolomide treat patient primary glioma .</brief_summary>
	<brief_title>Enzastaurin Temozolomide Treating Patients With Primary Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - To assess full dos enzastaurin hydrochloride temozolomide use combination treatment patient primary glioma . - To determine recommended phase II dose . OUTLINE : This multicenter study . Patients receive oral enzastaurin hydrochloride twice daily day 1-28* oral temozolomide daily day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . NOTE : *During first course , patient also receive enzastaurin hydrochloride day -1 . Patients undergo blood sample collection day 22 course 1 day 5 course 2 pharmacokinetic study enzastaurin hydrochloride . After completion study treatment , patient follow within 30 day every 3 month thereafter .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary supratentorial glioma WHO histologic grade 3 4 Patients undergone prior treatment lowgrade glioma transform glioblastoma ( biopsy proven ) allow Amenable standard temozolomide treatment First second recurrent disease prior surgery and/or radiotherapy OR newly diagnose disease amenable radiotherapy ( e.g. , multifocal disease ) PATIENT CHARACTERISTICS : ECOG WHO performance status 02 Hemoglobin ≥ 10.0 g/dL Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alkaline phosphatase transaminases ≤ 2.5 x ULN Serum creatinine &lt; 1.7 mg/dL Not pregnant lactate Negative pregnancy test Fertile patient must use effective contraception Clinically normal cardiac function No ischemic heart disease within past 6 month No clinically significant abnormality uncontrolled cardiac arrhythmia ECG QTc interval ≤ 450 msec ( male ) ≤ 470 msec ( female ) baseline 12lead ECG No history congenital long QTc syndrome No history stroke No prior concurrent malignancy within past 5 year except cone biopsied carcinoma cervix adequately treat basal squamous cell skin carcinoma No unstable systemic diseases No active uncontrolled infection No uncontrolled hypertension No psychological , familial , sociological , geographical condition would preclude study participation Must able swallow tablet PRIOR CONCURRENT THERAPY : See Disease Characteristics No 1 prior chemotherapy regimen adjuvant set first recurrence Prior temozolomide allow provided disease progression temozolomide treatment within 6 week complete temozolomide treatment Prior surgery primary brain tumor within past 3 month allow Patients receive corticosteroid treatment must stable decrease dose least 1 week study entry At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) At least 14 day since prior concurrent enzymeinducing antiepileptic drug include , limited , follow : Phenytoin Carbamazepine Phenobarbital More 30 day since prior concurrent investigational treatment No concurrent anticoagulant treatment ( e.g. , warfarin ) Low molecular weight heparin patient require anticoagulant therapy start study treatment may allow No concurrent routine use colonystimulating factor No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>